Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

As Published
http://dx.doi.org/10.1073/pnas.1518808112

Publisher
National Academy of Sciences (U.S.)

Version
Final published version

Accessed
Wed May 10 22:28:01 EDT 2017

Citable Link
http://hdl.handle.net/1721.1/108678

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.

Detailed Terms
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

Sara M. Tolaney,a,b 1 Yves Bouché,b,1 Dan G. Duda,b,1 John D. Martin,b,c,1,2 Giorgio Seano,c,d Marek Ancukiewicz,b,3 William T. Barry,a Shom Goel,b Johanna Lahdenranta,b,4 Steven J. Isakoff,b Eren D. Yeh,a Saloni R. Jain,b,c,5 Mehra Golshan,a Jane Broch,b Matija Snuderl,e,6 Eric P. Winer,a Ian E. Krop,b,7 and Rakesh K. Jain.7

Abstract

Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC) patients. To explore potential mechanisms of this benefit, we conducted a phase II study of neoadjuvant bevacizumab and adriamycin/cyclophosphamide/paclitaxel chemotherapy in HER2-negative BC. The regimen was well-tolerated and showed a higher rate of pathologic complete response (pCR) in triple-negative (TN)BC (11/21 patients or 52%, 95% confidence interval (CI): 30,74) than in hormone receptor-positive (HR)BC (5/78 patients or 6% (95% CI: 2.14)]. Within the HRBCs, basal-like subtype was significantly associated with pCR (P = 0.007; Fisher exact test). We assessed interstitial fluid pressure (IFP) and tissue biopsies before and after bevacizumab monotherapy and circulating plasma biomarkers at baseline and before and after combination therapy. Bevacizumab alone lowered IFP, but to a smaller extent than previously observed in other tumor types. Pathologic response to therapy correlated with sVEGFR1 postbevacizumab alone in TNBC (Spearman correlation 0.610, P = 0.0033) and pretreatment microvascular density (MVD) in all patients (Spearman correlation 0.465, P = 0.0005). Moreover, increased pericyte-covered MVD, a marker of extent of vascular normalization, after bevacizumab monotherapy was associated with improved pathologic response to treatment, especially in patients with a high pretreatment MVD. These data suggest that bevacizumab prunes vessels while normalizing those remaining, and thus is beneficial only when sufficient numbers of vessels are initially present. This study implicates pretreatment MVD as a potential predictive biomarker of response to bevacizumab in BC and suggests that new therapies are needed to normalize vessels without pruning.

Antiangiogenic therapy | circulating and tissue biomarkers | PAM50 gene signature | cellular proliferation

Ten drugs that target VEGF or its receptors have been approved for the treatment of various malignant diseases (1). However, bevacizumab, an anti-VEGF antibody, and other angiogenic agents (AAAs) that target the VEGF pathway have failed to provide an overall survival benefit to metastatic breast cancer (BC) patients (2). Preoperative (neoadjuvant) therapy is an effective way of treating certain BC patients, because this strategy leads to survival rates similar to those from postoperative therapy (3) while reducing the extent of surgery. Moreover, a favorable pathologic response to neoadjuvant therapy is associated with longer disease-free survival (4, 5). Recent studies report significant increases in the percentage of patients with no detectable residual disease—referred to as pathologic complete response (pCR)—with the addition of bevacizumab to neoadjuvant chemotherapy in human epidermal growth factor receptor 2 (HER2)-negative BC.

PNAS | November 17, 2015 | vol. 112 | no. 46 | 14325–14330

www.pnas.org/cgi/doi/10.1073/pnas.1518808112
B-40 study demonstrated a higher pCR rate in hormone receptor-positive BC (15.1% without bevacizumab vs. 23.2% with bevacizumab, \( P = 0.007 \)) but no statistically significant difference in TNBC (9). Moreover, two postoperative (adjuvant) trials of bevacizumab, BEATRICE and E5103, demonstrated no improvement in disease-free survival with the addition of bevacizumab to standard anthracycline-and taxane-based chemotherapy (2, 10). These inconsistent results underscore the need to identify mechanistic biomarkers of response to bevacizumab therapy.

There are two major hypotheses concerning AAs’ mechanism of action in tumors: (i) starving the tumor by blocking its blood supply and (ii) alleviating hypoxia by normalizing the function of tumor vasculature (1). Emerging functional imaging data in glioblastoma, nonsmall-cell lung cancer, and BC patients suggests that improved vascular function and the resulting increase in tumor oxygenation are associated with response to AAs (1, 11–15). However, there are no structural features of tumor vessels that can be used to predict the response (16), and the vascular changes induced by AAs to increase vessel function remain unclear. To complement the previous functional imaging studies with histological analysis of in situ changes in vascular structure in response to AA, we conducted a phase II trial of HER2-negative BC to investigate the neoadjuvant use of bevacizumab combined with standard of care dose-dense chemotherapy, which consists of doxorubicin and cyclophosphamide followed by paclitaxel (ACP). Neoadjuvant treatment enables pre- and posttherapy biopsies to explore potential mechanisms of action and biomarkers that may help select patients likely to benefit from AAs. In this exploratory correlative study, we evaluated biomarkers in serial biopsies, blood samples, and a functional marker of vascular normalization—tumor interstitial fluid pressure (IFP)—before and after a single dose of bevacizumab. Our results suggest that a high baseline microvascular density (MVD) in breast tumors may be necessary to benefit from bevacizumab-induced vascular normalization.

Results

Bevacizumab Combined with ACP Showed Superior Antitumor Activity in TNBC Compared with Hormone Receptor-Positive BC. A total of 104 patients were registered on study between November 2007 and June 2011 (Table S1). One patient did not initiate study treatment and was removed from the analysis; another patient withdrew consent; one was ineligible after rediagnosis with HER2+ BC; and two other patients were not evaluable for response because they did not complete therapy as per protocol due to toxicity. Therefore, 99 patients represent the efficacy population. A total of 103 patients (88%) completed all protocol therapy (Fig. S1). Of the 103 patients who initiated study treatment, 52 patients (50.5%) experienced grade ≥3 adverse events. The toxicities observed in this study were consistent with that observed in prior studies of similar bevacizumab/chemotherapy regimens (Table S2). pCR was observed in 16 of 99 patients, with greater responses seen within the TNBC cohort (52%, 95% confidence interval (CI): 30–74%) than within the hormone receptor-positive BC (HRBC) cohort (6%, 95% CI: 2–14%). This represents a 15-fold increase in the odds of pCR in TNBC over HRBC (\( P < 0.0001 \)). Similar differences were seen in residual cancer burden (RCB) (\( P < 0.0001 \)) and Miller–Payne (MP) scores (\( P = 0.0005 \)).

Gene Expression Profile Analysis Showed Differential Response in BC Subtypes. PAM50 gene signature, which measures expression profiles for 50 genes and classifies tumors into four intrinsic subtypes (luminal A, luminal B, HER2-enriched, and basal-like), was available for 70 patients in the efficacy population (Table S3). Within this group, there were 13 pCRs (19%). The distribution of responses did not differ between subjects with and without PAM50 data available. Of the 13 pCRs, 11 were seen within the basal-like subset, 1 within the luminal A subset, and 1 within the luminal B subset (Table S3). Overall, responses varied by subtype in terms of pCR (\( P < 0.0001 \)), MP (\( P = 0.0001 \)), and RCB (\( P < 0.0001 \)). Within the HR-positive subset with PAM50 data (\( n = 54 \)), there was insufficient power to contrast pCR among luminal tumors (one pCR each, luminal A and B). However, even within these HRBCs, basal-like subtype was significantly associated with pCR (\( P = 0.007 \); Fisher exact test).

Bevacizumab Treatment Exerts Effects Consistent with Vascular Normalization in BC. In patients with available biopsy and/or plasma samples, we examined the effects of bevacizumab treatment on biomarker levels related to vascular normalization (Tables S4–S6). We quantified all vessels in two biopsy sections per patient with custom software that automatically segmented CD31+ endothelial cells, αSMA+ perivascular cells (pericytes), and vessel lumen, combined them into vascular structures, and allowed manual confirmation of every selection (Fig. S2 and SI Methods). Bevacizumab reduced the intratumoral MVD (number of vessels per square millimeter; Fig. 1A), but not the density of mature vessels (pericycle-covered MVD (PC-MVD) and number of αSMA+ vessels per square millimeter; Fig. 1B and Table S4), indicating pruning of immature vessels, which lack pericytes, but not of mature vessels (Fig. S2A–C). Pruning of immature vessels likely increases the fraction of vessels that are pericycle-covered (number of αSMA+ vessels per number of vessels), but VEGF...
blockade may also promote maturation of nascent vessels through active pericyte recruitment, thereby increasing PC-MVD (17, 18). Through both mechanisms, bevacizumab increased the average proportion of vessel perimeter associated with pericytes (αSMA+, vessel surface length per total vessel length; Fig. 1C), leading to a reduction in IFP (Fig. 1D), presumably due to a decrease in vascular permeability (19). However, biomarkers of functional normalization such as fraction of proliferative cells (Ki67-positive) and fraction of tissue area positive for endogenous hypoxia marker HIF-1α did not significantly change (Fig. 1E and F). The only biomarker that differed between subtypes significantly in opposite directions was Ki67, because the fraction of proliferative cells increased in TNBC and decreased in HRBC (Fig. S3E and Table S4). Of note, bevacizumab also tended to increase cellular proliferation in lesions of colorectal cancer patients (20).

Among circulating biomarkers, bevacizumab therapy alone decreased plasma angiopoietin 2 (Ang-2), soluble Tie2 receptor (sTie2), and IL-1β and increased plasma VEGF, placental growth factor (PlGF), and carbon anhydrase (CA)1X (Table S5). During combination therapy, plasma Ang-2, TNF-α, IL-1β, IL-8, and stromal-derived factor (SDF)1α decreased, and plasma VEGF, PlGF, soluble (s) sVEGFR1 and sVEGFR2, basic fibroblast growth factor (bFGF), and IGF1 increased (Table S6). These changes after bevacizumab alone or combination therapy were consistent between BC subtypes, with the exception of sVEGFR2 (which did not increase in TNBC patients) and TNF-α (which did not decrease in HRBC patients) following combination therapy. After completion of neoadjuvant therapy, plasma Ang-2, IGF1, sVEGFR2, and IL-8 decreased whereas plasma VEGF, PlGF, sVEGFR1, bFGF, sTie2, IL-6, TNF-α, and CAIX increased (Table S6). Once again, the changes were largely consistent between BC subtypes, with the exception of sTie2 (not decreased in HRBC patients) and IGF1 (not increased in TNBC patients).

Baseline MVD, but Not Markers of Normalization, Associates with Pathologic Response in All Patients. Although the sample size precluded rigorous inferential statistical analysis, we explored the association between biomarkers and tumor regression in this patient population to generate hypotheses about potential mechanisms of action. Of all biomarkers, only baseline tumor MVD of both total and patent (i.e., with open lumen) vessels associated with both the RCB and MP tumor regression scores in all patients with evaluable samples (n = 52, Table 1). Postbevacizumab monotherapy, the increase in the fraction of cells positive for the proliferation marker Ki67 correlated with RCB (more relevant to prognosis after neoadjuvant therapy) but not MP (more relevant to neoadjuvant therapy’s effectiveness in killing cancer cells in primary tumors) regression scores (n = 45, Table 1).

In TNBC, the baseline HIF-1α area fraction (n = 11) and the postbevacizumab increase in PC-MVD (n = 7) were associated with both tumor regression scores (Table 1). Among circulating biomarkers in TNBC, tumor regression scores were associated with high plasma VEGF (at baseline) and low sVEGFR1 and PI GF levels (postbevacizumab monotherapy) (n = 21, Table S7). In TNBC at baseline, sVEGFR1 levels were associated with the fraction of the average proportion of vascular perimeter associated with pericytes (Spearman’s rho = 0.857, P = 0.024, n = 7). No other proangiogenic or inflammatory factor demonstrated any association with pathologic response.

Response to Bevacizumab in BC May Depend on Extent of Vascular Normalization Only in Patients with High Baseline MVD. The only biomarker of vascular normalization that correlated with response was change in PC-MVD after bevacizumab monotherapy, but the association held only in the 7 TNBC patients (Table 1) and not the 32 HRBC patients with data available at both baseline and postbevacizumab alone. We reasoned that baseline MVD could be an important distinguishing factor between TNBC and HRBC, because baseline MVD was 62.5% greater in TNBC (Fig. S3E) and correlated with RCB and MP scores in all patients (Table 1). Thus, we hypothesize that baseline MVD might be related to the lack of association of PC-MVD and tumor regression scores in HRBC.

To investigate this hypothesis, we classified high MVD HRBC patients as those with a baseline MVD greater than or equal to the lowest baseline MVD of a TNBC patient with pCR (MP = 5). We then used a standard cutoff point (MP >3) to differentiate patients with the greatest tumor response (reduction in tumor cellularity) postcombination therapy (SI Methods). Using MP score rather than the RCB score focused the analysis on the effect of combination therapy on the primary tumor. We evaluated whether PC-MVD increased in 19 patients (all 7 TNBC and 12 high MVD HRBC). Seventeen of 19 patients followed the pattern of stable or increased PC-MVD postbevacizumab alone in tumors with MP >3 and decreased PC-MVD in tumors with MP ≤3 (Fig. S4A and B and Table S8). Stable or increased PC-MVD implies pericyte recruitment to vessels. In contrast, fewer than half (8 of 20) of HRBC patients with low MVD followed this pattern (Table S8), which suggests that increased PC-MVD might not be related to tumor regression scores in patients with low baseline MVD. The fraction of pericyte-covered vessel perimeter in TNBC and high MVD HRBC patients also followed this pattern (Fig. S4C and D), whereas functional normalization biomarkers did not, nor was there an apparent connection between structural and functional biomarkers (Fig. S5).

Averages of these vascular biomarkers in all patients, regardless of baseline MVD, within the same groups of good (MP >3) or poor (MP ≤3) response postcombination therapy were

### Table 1. Correlations between in situ biomarker levels and MP pathologic regression score and RCB after neoadjuvant bevacizumab with dose dense chemotherapy

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Subtype</th>
<th>Time point</th>
<th>MP score</th>
<th>RCB</th>
</tr>
</thead>
<tbody>
<tr>
<td>MVD</td>
<td>All</td>
<td>Baseline</td>
<td>0.465</td>
<td>-0.364</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>0.0005</td>
<td>0.0079</td>
</tr>
<tr>
<td>Patent MVD</td>
<td>All</td>
<td>Baseline</td>
<td>0.507</td>
<td>-0.426</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>0.0001</td>
<td>0.0016</td>
</tr>
<tr>
<td>Proliferation (Ki67)</td>
<td>All</td>
<td>Fold change after bevacizumab</td>
<td>0.181</td>
<td>-0.416</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>0.258</td>
<td>0.0068</td>
</tr>
<tr>
<td>PC-MVD</td>
<td>TN</td>
<td>Fold change after bevacizumab</td>
<td>0.879</td>
<td>-0.852</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>0.0091</td>
<td>0.015</td>
</tr>
<tr>
<td>HIF-1a area fraction</td>
<td>TN</td>
<td>Baseline</td>
<td>-0.663</td>
<td>0.649</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>0.026</td>
<td>0.031</td>
</tr>
</tbody>
</table>

Data are shown as Spearman’s ρ values; significant correlations are highlighted in bold. Higher MP scores indicate better pathologic response. Lower RCB scores indicate better pathologic response. Positive values of Spearman’s ρ indicate a direct correlation between MP/RCB score with higher biomarker levels; P values are from the test of ρ = 0.
consistent with these results. At baseline, the tumor MVD was significantly higher in patients with MP >3 (Fig. 2A and Table S9). In these patients’ tumors, bevacizumab significantly reduced the MVD and increased the fraction of pericyte-covered vessel perimeter (Fig. 2A and B and Table S9). Despite the vascular pruning, PC-MVD trended toward an increase in patients with MP >3, suggesting pericyte recruitment contributed to the increased pericyte coverage (Table S9). Indeed, PC-MVD post-bevacizumab monotherapy was significantly higher in patients with MP >3 than in those with MP ≤3 (Fig. 2C and Table S9). Unlike the association between fold change of PC-MVD and tumor regression, which only occurred in TNBC (Table 1), in HRBC patients the pericyte-covered vessel perimeter significantly increased postbevacizumab in MP >3 tumors and PC-MVD was also significantly higher in MP >3 than in MP ≤3 tumors (Table S9). These results in HRBC are consistent with our hypothesis that low baseline MVD contributes to the lack of association between change in PC-MVD and tumor regression scores. Hence, in TNBC and high MVD HRBC patients with improved pathologic response postcombination therapy, bevacizumab induced vascular remodeling, which led to a higher density of normalized vessels (Fig. 3).

Discussion

BC is a complex disease composed of several biologically distinct subtypes (21). For patients with HRBC, only 5–10% of patients will achieve a pCR to preoperative chemotherapy. Recent neoadjuvant phase III trials showed that bevacizumab increases rates of pCR in HER2-negative BC, yet the results were inconsistent regarding which subtype benefits (6–9). Our study found that even with the addition of bevacizumab to dose-dense ACP chemotherapy, only 6.4% of HRBC patients achieved a pCR, in contrast to 52% of TNBC patients. The study was not powered to compare pCR rates between luminal A vs. luminal B BCs. However, among patients with either HRBC or TNBC, PAM50 data suggested an increase in response in those with the basal-like subtype, relative to other subtypes.

Serial biopsies enabled exploratory investigation of bevacizumab’s effects and mechanism of action in BC. Consistent with other tumor types, in BC bevacizumab pruned immature vasculature, induced maturation of vessels (as evidenced by increased pericyte coverage), reduced IIF, and changed levels of circulating biomarkers PlGF, VEGF, and Ang-2. Nonetheless, the magnitude of the decrease in IIF was less than that seen in rectal cancer (20, 22), which may indicate that either BC vessels are less sensitive to VEGF blockade or bevacizumab distribution in BC tissue is limited.

The effects of bevacizumab, though consistent with vascular normalization, did not correlate with pathologic response in all patients, because baseline MVD was the only biomarker to correlate with both RCB and MP scores in the 52 patients with data available. Although this patient cohort is too small for rigorous statistical analysis, these results suggest that a sufficiently high baseline MVD might be necessary for bevacizumab to aid primary tumor regression. A phase II trial in 20 BC patients also noted an association between expression of the endothelial cell marker CD31 and tumor regression (23). In patients with other tumor types treated with bevacizumab and cytotoxic therapy, correlations between baseline MVD and response have also been documented (24, 25), whereas other studies have found no relationship between MVD or MVD surrogates and response (26, 27). The exploratory nature of our current analysis notwithstanding, the association between MVD and tumor regression scores is consistent with the notion that vascular remodeling post-bevacizumab can convert some nonfunctional vessels into functional ones, but it cannot create new vessels. Thus, the function of the vascular network in tumors with high MVD and redundant vasculature (Fig. 3, top left) might benefit from the pruning of certain vessels and increased function of the remaining, normalized vessels (Fig. 3, top right). In contrast, tumors with low MVD (Fig. 3, bottom left) cannot overcome the paucity of vessels. In contrast, tumors with high baseline vascularity that recruit pericytes respond to bevacizumab combined with chemotherapy (top left quadrant to top right quadrant) better than tumors that undergo excessive pruning (top left quadrant to bottom right quadrant). Responders: MP scores of 4–5; nonresponders: MP scores of 1–3.

![Fig. 2](image-url) (A) The MVD at baseline is significantly higher (P = 0.0024) in patients with MP >3. In these patients, bevacizumab significantly reduced the MVD (P = 0.009). (B) Postbevacizumab the fraction of vessel perimeter covered by pericytes is significantly higher (P = 0.001) in patients with MP >3. (C) Postbevacizumab PC-MVD is significantly higher (P = 0.008) in patients with MP >3.

![Fig. 3](image-url) A schematic of the proposed mechanism of action of benefit from antiangiogenic therapy. The left two quadrants depict tumor vessels (red) at baseline before bevacizumab monotherapy, and the two right quadrants depict the vasculature following bevacizumab monotherapy. In the top left quadrant, there is a higher vascular density (MVD) than in the bottom left quadrant. Tumors with insufficient baseline MVD do not respond to antiangiogenic therapy (bottom left to bottom right quadrants), because the increase in functional vessels resulting from the recruitment of pericytes (teal) cannot overcome the paucity of vessels. In contrast, tumors with high baseline vascularity that recruit pericytes respond to bevacizumab combined with chemotherapy (top left quadrant to top right quadrant) better than tumors that undergo excessive pruning (top left quadrant to bottom right quadrant).
Thus, our results indicate that tumor regression from VEGF blockade might be restricted to tumors with a sufficiently high MVD and might occur through pericyte recruitment rather than vascular pruning, leading to an increased extent of vascular normalization.

We found several biomarkers that associated with tumor regression in TNBC, including high VEGF levels at baseline and low sVEGFR1 and PIGF levels before combination treatment (Table S7). Changes of sVEGFR1 levels—a factor linked with "vascular normalization" (37) that we proposed as a resistance biomarker to neoadjuvant bevacizumab in rectal cancer (40)—was directly associated with pericyte coverage and inversely associated with response. Two phase III randomized trials of bevacizumab have shown that specific VEGFR1 SNPs correlated with high VEGFR1 expression and poor outcome (41). In addition, we have reported results from an adequate number of plasma sVEGFR1 and treatment outcomes after anti-VEGF therapies in patients with metastatic colorectal (vandetanib plus cetuximab/irinotecan), hepatocellular carcinoma (cediranib monotherapy), sarcoma (sorafenib), and lung cancer (bevacizumab plus chemotherapy) (12, 42–44). Finally, although plasma PIGF (a growth factor not blocked by bevacizumab) consistently increased in these BC patients, the extent of this increase was associated with lower tumor regression scores in TNBC patients. This association with less regression warrants further exploration of this potential mechanism of resistance to anti-VEGF therapy in TNBC.

In summary, bevacizumab induced changes in vascular structure and levels of circulating biomarkers indicative of vascular normalization in BC, although these changes were small compared with other tumor types. Baseline MVD was associated with tumor regression, indicating that many BCs might be insufficiently vascularized to yield improvement in perfusion or oxygenation because anti-VEGF therapy-induced pruning of immature vessels may outgrow the number of normalized vessels, leaving an insufficient number of functional vessels. In patients with relatively high baseline MVD, response may result from inadequate number of normalized vessels, as evidenced by increased PC-MVD. However, the potential mechanistic link between sufficient MVD and changes in PC-MVD with tumor regression needs to be confirmed through simultaneous biopsies and functional imaging studies in larger clinical studies (45). The observed association of circulating biomarkers with regression in TNBC is consistent with previous studies in BC and other tumor types and reveals a potential connection between sVEGFR1 and vascular maturity. Together, these results suggest that in poorly perfused BCs and other hypoperfused tumors (e.g., pancreatic ductal adenocarcinoma), strategies that increase perfusion without pruning—targeting alternative angiogenic pathways (46), directly inducing differentiation of intratumoral sources of pericyte progenitors (47), and increasing vessel patency by reducing solid stress (31–33) or enhancing lumen formation (48)—should be explored (1, 49).

**Methods**

**Patients and Treatment Regimen.** Enrollment required a pathological diagnosis of adenocarcinoma of the breast. Two cohorts of patients were eligible: patients with HRBCs and patients with TNBC. Additional information about patient eligibility and ineligibility requirements, and treatment regimen are described in SI Methods. This study was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. Written informed consent was required for enrollment.

**Tumor Genomic and Correlative Analyses.** The experimental procedures for IFP measurements, analysis of tissue and circulating biomarkers, and statistical analyses are described in SI Methods.

**ACKNOWLEDGMENTS.** The authors thank Drs. James Baish, Vikash Chauhan, Kyrre Emblem, Dai Fukumura, Joao Incio, and Triantafyllos Stylianopoulos for their helpful comments on the manuscript and Carolyn Smith for technical assistance. The clinical trial was supported by a Genentech grant (to S.M.T., I.E.K., and E.P.W.) and AVON National Cancer Institute Institute for Patients Program Grant 2P50 CA089393-0852 (to Dr. Dick J. Joglekar). Correlative...


